论文部分内容阅读
目的研究非ST段抬高性心肌梗死患者PCI治疗前后血浆不对称二甲基精氨酸(ADMA)浓度的变化及丹参对其的影响。方法 52例均为非ST段抬高性心肌梗死并接受PCI治疗的患者,随机分为两组:丹参组(26例)患者在常规治疗基础上加用丹参(1 g,每日3次)至PCI术后1个月,对照组(26例)只接受常规治疗。分别在PCI术前、术后第1、30天检测患者血浆ADMA浓度。结果与术前比较,2组术后30天ADMA水平均明显下降,差异有统计学意义(均P<0.01),同时丹参组下降较对照组更明显,差异有统计学意义(P<0.01)。结论非ST段抬高性心肌梗死患者应用PCI治疗可下调ADMA水平,PCI患者应用丹参对ADMA的负性调节可能与改善预后有关。
Objective To investigate the changes of plasma asymmetric dimethylarginine (ADMA) concentrations in patients with non-ST-segment elevation myocardial infarction before and after PCI and the effect of Salvia miltiorrhiza on it. Methods Fifty-two patients with non-ST-segment elevation myocardial infarction who were treated with PCI were randomly divided into two groups: Salvia miltiorrhiza group (26 cases) received Salvia miltiorrhiza (1 g, 3 times a day) One month after PCI, the control group (26 cases) received routine treatment only. The levels of plasma ADMA in patients were measured before PCI and on the 1st and 30th day after PCI respectively. Results Compared with the preoperative level, the levels of ADMA in two groups were significantly decreased at 30 days after operation (all P <0.01), while the decrease in Salvia miltiorrhiza group was more significant than that in control group (P <0.01) . Conclusion Non-ST-elevation myocardial infarction in patients with PCI treatment can reduce the level of ADMA, PCI patients with ADAM negative control Salvia may be related to improving prognosis.